Dolor de cabeza (tensión)

A Phase II clinical trial found that 30 g/day of gum arabic for 12 weeks in RA patients significantly decreased TNF-α and disease severity scores, and improved hepatic and renal profiles that are often compromised by RA pathology and RA medications. The anti-inflammatory mechanism involves SCFA-mediated cytokine suppression.

ALA reduces RA-associated inflammatory mediators by shifting eicosanoid synthesis from pro-inflammatory to anti-inflammatory pathways. A placebo-controlled RCT in RA patients using flaxseed oil supports anti-inflammatory benefit.

DHA and EPA from omega-3 sources including algal oil reduce inflammation and cytokine levels relevant to rheumatoid arthritis pathophysiology. Multiple clinical studies show reductions in plasma IL-1β, TNF-α, and IL-6 with fish oil supplementation—directly applicable to algal oil given confirmed bioequivalence. Omega-3s provide complementary anti-inflammatory benefit in RA management.

Aloe vera has been traditionally prescribed for rheumatoid arthritis (RA), and scientific evidence confirms anti-inflammatory mechanisms relevant to RA pathophysiology. Acemannan and anthraquinones modulate cytokines (TNF-α, IL-6, IFN-γ) central to RA. A 2025 PMC review specifically explored aloe vera anthraquinones as modulators of autoimmune/inflammaging mechanisms including RA.

A quasi-experimental study (n=45 RA patients) found warm A. galanga compresses significantly reduced RA pain scores (p<0.001). In vitro, A. galanga extract downregulates IL-1β-induced MMP expression in human synovial fibroblasts. Animal models show dose-dependent anti-arthritic effects.

Andrographis paniculata and its active constituent andrographolide have anti-inflammatory and immunomodulatory effects relevant to RA. ConsumerLab describes clinical evidence showing andrographis can help relieve pain and stiffness of RA. The branded ParActin extract has been specifically evaluated in RA clinical trials.

Andrographolide, the principal bioactive of Andrographis paniculata, potently inhibits NF-κB and reduces TNF-α, IL-1β, and IL-6 production. Multiple preclinical studies in collagen-induced arthritis models and clinical evidence with the standardized ParActin extract support its use as an adjunct in RA for reducing joint pain and stiffness.

Sarsasapogenin, a primary metabolite of anemarrhena saponins, exerts anti-arthritic effects in rheumatoid arthritis models by suppressing pathological glycolysis in fibroblast-like synoviocytes via PKM2 targeting and modulating NF-κB/HIF-1α pathways.

Ashwagandha (Withania somnifera) has been used in Ayurvedic medicine for joint inflammation for millennia. Withanolides inhibit NF-κB and pro-inflammatory cytokines relevant to RA. Clinical trials have shown reduced pain and inflammation in arthritis patients; animal studies confirm anti-arthritic activity in collagen-induced arthritis models.

Astaxanthin is a ketocarotenoid antioxidant from Haematococcus pluvialis that inhibits NF-κB, reduces IL-6 and TNF-α, and provides antioxidant protection relevant to RA oxidative stress. It is included in krill oil (a studied RA supplement) and in stand-alone joint health formulas; preclinical evidence in arthritis models supports its anti-inflammatory activity.

APS treatment reduced multiple indices of arthritis in adjuvant-induced arthritis (AA) rat models, supporting investigation for RA. In RA fibroblast-like synoviocytes, APS induced autophagy via PI3K/Akt/mTOR and suppressed proinflammatory cytokine production. Traditional Chinese medicine includes astragalus use for articular rheumatism.

Atractylodes macrocephala extract combined with strychnine has been studied in rheumatoid arthritis synoviocyte cell lines (MH7A), inhibiting the TLR4/NF-κB/NLRP3 pathway. Atractylodes lancea features in the classical Ermiao Pill used for RA in Chinese clinical practice. Evidence is preclinical.

A randomized, double-blind, placebo-controlled pilot trial (n=45) found that B. coagulans GBI-30, 6086 added to standard RA therapy produced statistically significant improvement in Pain Scale (p=0.046) and greater improvements in patient global assessment, CRP, and functional capacity vs. placebo. The gut-immune axis is the proposed mechanistic link.

Baicalein is the aglycone of baicalin from Scutellaria baicalensis, with potent anti-inflammatory effects including inhibition of NF-κB, TNF-α, IL-1β, and LOX pathways. Preclinical studies in collagen-induced arthritis models show reduced synovial inflammation and bone erosion, making it relevant as a complementary approach to RA management.

Baicalin, a flavone glycoside from Baikal skullcap (Scutellaria baicalensis), has documented anti-inflammatory and immunomodulatory effects relevant to RA. It was included as an active arm in a 2025 network meta-analysis of 18 RA RCTs (1,674 patients), and preclinical studies confirm reduction of synovial inflammation and bone erosion in arthritis models.

Barberry and berberine have shown immunomodulatory effects specifically in rheumatoid arthritis, reducing joint inflammation and increasing anti-inflammatory cytokines. Experimental studies support berberine's modulation of PI3K/Akt and other RA-relevant signalling pathways. Herbal Reality references clinical evidence showing barberry reduces inflammation and increases anti-inflammatory cytokines in RA.

Epimedium sagittatum has been studied for immunomodulatory and anti-inflammatory effects relevant to rheumatoid arthritis, including inhibition of TLR4/MD-2-mediated NF-κB signaling and reduction of TNF-α. Epimedium is listed in ethnopharmacological reviews as a treatment for rheumatic arthritis. Preclinical evidence supports immune and inflammatory target engagement; human RA-specific trials have not been published.

Bee venom (BV) has been used in traditional Oriental medicine for RA for centuries, and modern research confirms its anti-inflammatory effects via melittin-mediated COX-2 inhibition and apoptosis of rheumatoid synovial cells. Multiple clinical trials of bee venom acupuncture (BVA) in RA and a systematic review protocol exist, with preclinical CIA models showing significant benefit.

A double-blind, placebo-controlled RCT in RA patients (1 g/day N. sativa oil for 8 weeks) demonstrated significant reductions in inflammatory cytokines and oxidative stress markers. Multiple meta-analyses including RA patients show significant CRP reduction with N. sativa supplementation.

Borage seed oil is one of the best-evidenced herbal interventions for rheumatoid arthritis, supported by multiple RCTs and a Cochrane systematic review showing moderate evidence for GLA-containing oils in reducing RA pain intensity, tender joint count, and swelling. The mechanistic basis—GLA suppression of TNF-alpha and pro-inflammatory eicosanoids—is well characterised.

Multiple RCTs and a Cochrane systematic review provide moderate evidence that borage seed oil's GLA content reduces RA pain, joint tenderness, and disability. A landmark 1993 double-blind trial (n=37, 24 weeks) found a 36% reduction in tender joints and 45% reduction in tenderness scores. A Cochrane review of seven GLA-oil studies found statistically significant reductions in pain and disability. Evidence is moderate; optimal dose and duration remain uncertain.

Boswellic acids, especially AKBA, inhibit 5-lipoxygenase (5-LOX), reducing inflammatory leukotrienes that attack joints. Multiple RCTs and a 2014 Cochrane Review support its use for inflammatory joint conditions including RA, reducing pain and improving joint function. Used in Ayurveda for centuries for inflammatory diseases.

Boswellic acids are the active constituents of Boswellia serrata resin, with AKBA being the most potent anti-inflammatory compound. They inhibit 5-LOX and NF-κB, reducing leukotrienes and pro-inflammatory cytokines relevant to RA pathogenesis. Clinical and preclinical evidence supports their role as adjunct therapy in RA.

Sulforaphane inhibits NF-κB-driven synovial inflammation and reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that drive rheumatoid arthritis (RA) pathology. Human macrophage studies demonstrate that SFN from broccoli potently reduces both M1 and M2 macrophage inflammatory activity, relevant to RA's immune dysregulation.

Bromelain has documented clinical use in rheumatoid arthritis (RA) dating to early case reports, and has been recommended as an adjuvant therapeutic approach in chronic inflammatory and autoimmune diseases. It suppresses TNF-α–induced NF-κB and MAPK signaling, modulates TGF-β expression in RA patients, and reduces inflammatory cytokines in synovial fibroblasts. Multiple clinical studies and PMC reviews confirm evidence of benefit.

A 2025 PMC study tested Arctium lappa root extract in a Complete Freund's Adjuvant (CFA)-induced arthritis rat model, a standard RA preclinical model, and confirmed significant antioxidant and anti-inflammatory effects. Herbal Reality cites burdock's anti-inflammatory and antioxidant properties as beneficial for rheumatoid arthritis. Traditional use across multiple herbal traditions consistently includes rheumatism.

Clinical and preclinical studies show omega-3 PUFAs including DHA and EPA reduce joint inflammation and destruction in rheumatoid arthritis (RA). A 2022 study found omega-3 consumption improved symptoms of inflammatory rheumatic diseases. Alberta Rheumatology notes conflicting evidence but acknowledges omega-3s are used for RA management with a likely safe profile.

A meta-analysis and systematic reviews document campesterol's antiarthritic effects in preclinical RA models, with evidence for cytokine modulation relevant to RA pathophysiology. Campesterol ester derivatives reduced paw edema, pain hypersensitivity, and pro-inflammatory cytokine expression in CFA-induced rat RA models. Evidence is currently preclinical; no human RCTs specific to RA have been published.

The 1991 double-blind RCT (Deal et al., Clin Ther) enrolled 31 RA patients alongside 70 OA patients; capsaicin cream produced significantly greater pain relief than placebo. Substance P is implicated in rheumatoid synoviocyte activation, providing the mechanistic rationale. Clinical evidence supports topical capsaicin as an adjunct in RA.

Topical capsaicin reduces pain and inflammatory mediators in rheumatoid arthritis patients in clinical studies, and capsaicin is listed as an established use for RA. Mechanistic research demonstrates capsaicin targets fibroblast-like synoviocytes via PRDX2 inhibition, reducing joint inflammation.

BCP significantly reduced arthritis severity in the CAIA mouse model—a well-validated RA surrogate—by suppressing pro-inflammatory cytokines, reducing MMPs 3 and 9, and activating PPAR-γ via CB2 crosstalk. Evidence is preclinical only.

Cat's claw (Uncaria tomentosa) contains oxindole alkaloids that decrease TNF-alpha via NF-κB inhibition, and polyphenols with antioxidant effects. Small controlled trials suggest beneficial effects on pain in chronic RA, and the Arthritis Foundation and EBSCO list it among proposed natural treatments for RA.

Studies of erythrocyte and synovial antioxidant enzyme activity in rheumatoid arthritis (RA) patients document altered catalase activity alongside elevated oxidative stress markers. Oxidative stress is a well-recognized pathogenic driver in RA, with ROS amplifying joint inflammation and cartilage destruction.

Multiple double-blind trials demonstrate topical capsaicin cream provides significant pain relief in rheumatoid arthritis by depleting substance P at peripheral joint nociceptors. PeaceHealth's evidence-based summary and Cochrane-referenced literature confirm this indication, with topical capsaicin used as an adjunct to standard RA therapy.

A preliminary clinical study evaluated S. media extract in patients with polyarticular inflammatory arthritis, finding reductions in inflammatory markers. Animal models also show anti-inflammatory and analgesic effects. Traditional use for rheumatic conditions is long-documented.

Salvia miltiorrhiza compounds, particularly tanshinone IIA, suppress synovial inflammation, reduce TNF-α/IL-6, and inhibit osteoclast-mediated bone destruction relevant to RA pathophysiology. Traditional use for joint pain and rheumatism is long-standing. Pharmacological data are strong; large dedicated clinical RA trials are still emerging.

Chondroitin sulfate is a structural glycosaminoglycan that may reduce joint inflammation and cartilage degradation in arthritis. It is listed among proposed natural treatments for RA by multiple authoritative sources, and is commonly used alongside glucosamine as an adjunct therapy.

In a CFA-induced rheumatoid arthritis rat model, chrysin at 50 and 100 mg/kg significantly reduced arthritis score, rheumatoid factor, ESR, TNF-α, NF-κB, and TLR-2 expression, with effects comparable to piroxicam. Histopathology confirmed reduced cartilage erosion, bone erosion, and pannus formation. Evidence is preclinical.

A 2018 randomized double-blind clinical trial in 36 women with RA showed that 2 g/day cinnamon for 8 weeks significantly reduced CRP and TNF-α vs. placebo, and improved clinical disease activity. The authors concluded cinnamon is a safe and potentially useful adjunct treatment for RA.

CLA has been studied in RCTs in active rheumatoid arthritis (RA) patients. Combined CLA plus vitamin E supplementation reduced morning pain and joint stiffness and showed favorable bone marker effects in RA patients. CLA inhibits TNF-α and COX-2, key inflammatory mediators in RA.

SKI306X, a standardized extract containing C. mandshurica, was compared to celecoxib in a 6-week multicenter, randomized, double-blind Phase III non-inferiority trial in 183 Korean rheumatoid arthritis patients and was found non-inferior for pain relief. In vitro, SKI306X suppressed Th17 cytokine-induced TNF-α, IL-1β, and osteoclastogenesis in synovial fibroblasts from RA patients.

Eugenol from clove is indicated in traditional and pharmacological literature for rheumatoid arthritis. It lowers uric acid, inhibits COX-2 and NF-κB, and is listed as a rheumatoid arthritis treatment in PMC pharmacological reviews of Syzygium aromaticum.

Cod liver oil's EPA and DHA suppress the inflammatory mediators that drive rheumatoid arthritis. Clinical trials have shown reductions in morning stiffness, swollen and painful joints, and NSAID requirements. A double-blind RCT found 39% of RA patients could reduce daily NSAID use by >30% with cod liver oil supplementation.

Coix seed extract significantly reduced joint inflammation, paw edema, PGE2, and MMP-3 in a CFA-induced RA rat model. A 2025 multi-omics study identified coix seed oil's mechanism in CIA rats as suppression of NLRP3 inflammasome via the gut-butyrate-joint axis.

Oral type II collagen (undenatured) induces immune tolerance to cartilage antigens in RA via gut-associated lymphoid tissue, reducing autoimmune attacks on joints. A clinical study in RA patients found type II collagen at low doses (0.1–0.5 mg/day) produced substantial joint improvement including reduction in swollen joints, and ConsumerLab lists collagen hydrolysate among RA supplements under study.

Copper metabolism is demonstrably altered in rheumatoid arthritis (RA): meta-analyses show elevated serum copper in RA patients versus controls. Copper complexes have anti-inflammatory properties relevant to RA, and RA patients carry increased ceruloplasmin as an acute-phase reactant. Clinical studies on copper supplementation in RA are limited but the biochemical relationship is established.

A population-based prospective study found BCX intake was 40% lower in incident inflammatory polyarthritis/RA cases. Higher BCX plasma levels are associated with lower RA risk in epidemiological studies of adults aged 45–75. Animal data show anti-arthritic effects on antigen-induced arthritis.

Curcumin, the active polyphenol from turmeric, inhibits COX-2, 5-LOX, NF-κB, and multiple pro-inflammatory cytokines implicated in RA. A 2025 network meta-analysis of 18 RCTs found curcumin superior to placebo in reducing swollen and tender joint counts and inflammatory markers. Typical effective dose is 500–1000 mg/day of standardized extract.

Blackcurrant seed oil has been tested directly in RA patients in a published 24-week RCT, producing statistically significant reductions in signs and symptoms of disease activity. GLA's anti-inflammatory pathway via DGLA and prostaglandin E1 is well-characterized mechanistically.

Vitamin E (alpha-tocopherol) has low-level clinical evidence for reducing pain, stiffness, and inflammatory markers in rheumatoid arthritis as an adjunct therapy. RCTs have examined it alone and in combination with other nutrients, and an active registered clinical trial is currently evaluating its effect on RA clinical activity.

Devil's claw (Harpagophytum procumbens) contains harpagoside and harpagide, iridoid glycosides with anti-inflammatory and analgesic properties. A review found it effective for pain in rheumatic disorders including RA, and an open study of 259 patients with arthritis and other rheumatic conditions demonstrated statistically significant improvements in pain, stiffness, and function.

DHA is an omega-3 fatty acid that, along with EPA, forms the anti-inflammatory basis of fish oil therapy in RA. It reduces prostaglandin and leukotriene synthesis, modulates immune cell function, and generates anti-inflammatory resolvins D. Combined EPA+DHA supplementation significantly reduces RA clinical activity in multiple RCTs.

Low DHEA levels have been consistently observed in rheumatoid arthritis (RA) patients. DHEA has anti-inflammatory and immunomodulatory properties including inhibition of proinflammatory cytokine production and NF-κB activation. Animal studies show DHEA supplementation improves experimental arthritis; limited clinical evidence exists but RA is among the autoimmune conditions for which DHEA benefits have been noted.

Docosahexaenoic acid (DHA) from marine oils reduces pro-inflammatory eicosanoids and generates anti-inflammatory resolvins D relevant to RA. Combined with EPA, it is among the most evidence-supported natural interventions for RA, with multiple RCTs and meta-analyses demonstrating reduced joint tenderness, morning stiffness, and NSAID use.

Rosa canina has traditional use for rheumatoid arthritis and preliminary clinical evidence from an RCT by Willich et al. (Phytomedicine, 2010) demonstrating symptom improvement. One prospective cohort study (n=20 RA patients) found no significant change in CRP at 28 days. Evidence is preliminary and weaker than for osteoarthritis.

Multiple preclinical studies demonstrate that A. sinensis extracts and its polysaccharides suppress key RA pathogenic mechanisms: they inhibit synovial fibroblast proliferation, downregulate COX-2, PGE2, and matrix metalloproteinases, and restore macrophage M1/M2 balance. Ferulic acid suppresses RANKL-induced osteoclast differentiation. Evidence is entirely preclinical; no human RCTs for Dong Quai in RA have been identified.

EGCG is the principal bioactive catechin in green tea with potent anti-inflammatory effects in RA, including inhibition of NF-κB, COX-2, TNF-α, IL-6, and matrix metalloproteinases. Multiple preclinical studies in collagen-induced arthritis models and cell culture work with RA synoviocytes demonstrate significant anti-arthritic activity.

Eicosapentaenoic acid (EPA) from marine oils reduces RA-relevant inflammatory eicosanoids and generates anti-inflammatory resolvins. At least 12 double-blind RCTs demonstrate clinical benefit in RA including reduced tender joints, morning stiffness, and NSAID requirements. Supported by multiple systematic reviews and the Arthritis Foundation.

The same Freund's adjuvant preclinical study that characterized anti-arthritic activity explicitly evaluated and proposed E. littorale as a candidate for rheumatoid arthritis control, based on reduced paw edema and antioxidant protection. Traditional use across Siddha and Ayurveda for rheumatism (Vata disease) is well-documented.

EPA is an omega-3 fatty acid from fish oil that competitively inhibits arachidonic acid metabolism, reducing pro-inflammatory PGE2 and LTB4 in RA. Multiple RCTs demonstrate that EPA-containing marine oil supplementation reduces tender joints, morning stiffness, and NSAID use in RA patients.

A published RCT specifically in rheumatoid arthritis patients demonstrated that eucalyptus oil inhalation significantly reduced pain severity and improved quality of life over one month. The anti-cytokine and NF-κB inhibitory mechanisms of 1,8-cineole are highly relevant to the pathophysiology of RA. This represents adjunct symptomatic benefit, not disease modification.

E. ulmoides extracts significantly reduced joint inflammation, synovial cytokines, joint destruction, and MMP-9 expression in the collagen-induced arthritis (CIA) rat model—a standard preclinical model of rheumatoid arthritis. Effects were comparable across multiple extract fractions. Human trials are absent.

Evening primrose oil (EPO) provides gamma-linolenic acid (GLA), which reduces RA symptoms by competing with arachidonic acid in inflammatory pathways. A Cochrane review of 7 RCTs found GLA-containing oils (including EPO) significantly reduced pain intensity and improved disability in RA. Clinical trials show modest but meaningful benefits.

Feverfew has been specifically studied for rheumatoid arthritis in a double-blind, placebo-controlled RCT of 40 patients, which showed no significant clinical benefit. Preclinical data demonstrate that parthenolide inhibits ICAM-1 on synovial fibroblasts, reduces T-cell adhesion, and suppresses IL-1β and TNF-α in chondrocytes relevant to RA pathogenesis.

Fish oil, rich in EPA and DHA, is the most extensively studied natural supplement for RA. At least 12 placebo-controlled double-blind RCTs document clinical improvements including reduced morning stiffness, tender joints, and NSAID requirements. A 2017 systematic review of 22 marine oil trials found moderate-quality evidence for benefit in RA.

Clinical trials specifically in RA patients show that whole flaxseed (30 g/day) can reduce disease activity scores, pain, and morning stiffness. Flaxseed oil (3 g/day) in one RCT outperformed fish oil for RA symptom reduction. Evidence for flaxseed oil alone is limited per institutional reviews.

Rheumatoid arthritis (RA) is specifically listed in the Chinese Pharmacopeia as an indication for dried C. speciosa fruit. The glucosides, polysaccharides, and triterpenoids of C. speciosa suppress collagen-induced arthritis in rodents and inhibit MAPK signaling, cytokine production, and synovial inflammation. One small Chinese clinical observation report exists, but RCT-level human evidence is lacking.

Folic acid is essential in RA management primarily as a supplement prescribed alongside methotrexate (the anchor DMARD for RA) to reduce methotrexate-induced toxicity including mucositis, hepatotoxicity, and gastrointestinal side effects. It is listed by EBSCO as a proposed natural treatment for RA.

Folinic acid (leucovorin) is used alongside low-dose methotrexate (MTX) therapy for rheumatoid arthritis to reduce MTX-related toxicity. A Cochrane systematic review found that folate supplementation (folic or folinic acid) reduces abnormal liver function tests and treatment discontinuation, with no clear clinical advantage of folinic acid over folic acid. Folinic acid does not appear to diminish MTX's therapeutic efficacy.

Geniposide from Gardenia jasminoides demonstrated anti-rheumatic activity in adjuvant-induced arthritis rat models, inhibiting synoviocyte hyperpermeability via RhoA/p38MAPK/NF-κB/F-actin signaling and reducing paw swelling and synovial inflammation. It is listed in preclinical literature as a therapeutic candidate for rheumatoid arthritis alongside IBD and neurodegenerative disorders.

A double-blind RCT in 70 RA patients found garlic tablets (1 g/day for 8 weeks) significantly improved disease activity score, tender joint count, pain VAS, and CRP versus placebo. Garlic's anti-inflammatory mechanism—inhibiting TNF-α, IL-1β, and COX—is directly relevant to RA pathology.

Gentiopicroside, the primary secoiridoid from Gentiana species used in traditional Chinese medicine for RA, has been studied in a collagen-induced arthritis (CIA) rat model (Scientific Reports, 2025), showing inhibition of inflammatory responses and osteoclastogenesis. Network pharmacology and molecular docking confirm multiple RA-relevant targets. No human RCTs have been conducted.

Gentiana macrophylla (Qin Jiao) is used in TCM for rheumatoid arthritis and has the strongest experimental evidence among gentian species for this use. A rat study showed oral G. macrophylla extract at 100 mg/kg significantly reduced PGE2 in inflammatory tissues, paw swelling, and ankle circumference, with anti-inflammatory potency comparable to prednisone. Gentiopicroside, the key iridoid, suppressed the ROS-NF-κB-NLRP3 pathway in human RA fibroblast-like synoviocytes in vitro. Evidence is preclinical; no human RCT exists.

Multiple preclinical studies demonstrate that Gentiana macrophylla root extract significantly inhibits rheumatoid arthritis markers in rat models. The primary active compound, gentiopicroside, reduces PGE2, TNF-α, IL-1β, and IL-6, and suppresses NF-κB signaling. Anti-inflammatory potency has been compared favorably to prednisone in animal studies. Clinically, it is one of the principal TCM herbs used in RA management.

Ginger (Zingiber officinale) contains gingerols and shogaols that inhibit COX and LOX enzymes, reducing prostaglandin and leukotriene synthesis involved in RA inflammation. Multiple RCTs found ginger supplementation reduced tender joint counts, morning stiffness, and CRP in RA patients. Typical studied dose is 1,000–1,500 mg/day.

GLA from evening primrose, borage, or blackcurrant seed oil is supported by a Cochrane review of 7 RCTs for RA, showing reduced pain intensity and improved disability versus placebo. GLA is metabolized to DGLA, which competitively inhibits arachidonic acid pathways and directly suppresses T lymphocytes.

Glucosamine is a natural amino-monosaccharide and cartilage component. A double-blind, placebo-controlled trial of 51 RA patients found that 1,500 mg/day of glucosamine significantly improved RA symptoms. It is widely used for arthritic conditions and is among the most commonly employed complementary medicines in RA populations.

Clinical studies of Phytodolor (a combination containing goldenrod, aspen, and ash) specifically reported efficacy in rheumatoid arthritis subtypes, with outcomes comparable to NSAID treatment. Anti-inflammatory mechanisms of goldenrod constituents including flavonoids and leiocarposide are pharmacologically characterized. Evidence is limited to combination-product studies.

Madecassoside, a primary triterpene in Gotu Kola, has demonstrated anti-rheumatoid arthritic effects in a collagen-induced arthritis mouse model, reducing joint inflammation, cartilage erosion, and bone erosion. MSKCC notes the active constituent madecassoside may have antiarthritic effects. Evidence in humans is limited to traditional use and extrapolated preclinical data.

Green chiretta is directly supported by a published randomised, double-blind, placebo-controlled trial for rheumatoid arthritis, demonstrating significant reduction in swollen and tender joints, functional disability scores, and rheumatoid factor. This is one of the few herbal medicines with direct RCT evidence in RA.

Green tea polyphenols, particularly EGCG, inhibit TNF-α, IL-6, IL-1β, COX-2, and NF-κB signaling pathways relevant to RA. A 2025 PMC-published comprehensive review confirms green tea polyphenols inhibit RA-relevant inflammatory mediators, and Harvard Health, Arthritis Foundation, and PubMed reviews list green tea among herbs under clinical investigation for RA.

Green-lipped mussel (Perna canaliculus) from New Zealand provides anti-inflammatory omega-3 fatty acids including eicosatetraenoic acid, along with glycosaminoglycans. A 2006 Clinical Rheumatology review found benefit in 2 of 5 RA trials, and animal studies in CIA mice demonstrate reduced arthritis severity and pro-inflammatory cytokines.

Guggulipid targets multiple molecular pathways central to rheumatoid arthritis pathophysiology, including COX-2, NF-κB, and JAK/STAT. Early clinical research suggests 3,000 mg/day for 4 months may improve RA symptoms. Ayurvedic formulations such as Vatari Guggulu have been evaluated in small controlled trials with reported benefits in joint swelling and pain.

Intra-articular HA injection has been studied in rheumatoid arthritis (RA) patients, particularly for joints with concurrent osteoarthritis. Serum HA levels are elevated in active RA and correlate with disease activity markers. Clinical trials are limited in number and size; most evidence comes from RA patients with coexistent knee osteoarthritis rather than pure inflammatory RA.

Halofuginone, derived from Dichroa febrifuga (a hydrangea-family plant from Chinese medicine), was shown in a 2009 Science study to selectively inhibit Th17 cell differentiation in human and mouse T cells. Th17 cells are established drivers of synovial inflammation and joint destruction in rheumatoid arthritis. TCM also lists rheumatoid arthritis as an indication. Evidence is mechanistic/preclinical; no human RA trials exist.

Boswellia serrata has traditional use for rheumatoid arthritis and preclinical evidence in collagen-induced arthritis animal models, showing reductions in arthritic index, paw volume, inflammatory cytokines (IL-1β, IL-6, TNF-α), and anti-collagen antibodies comparable to celecoxib. A 2008 systematic review identified clinical trials in RA, and it is included in lifestyle intervention meta-analyses for RA, though robust dedicated human RA RCTs are fewer than for OA.

A clinical study of 40 rheumatoid arthritis patients taking 30 g/day gum arabic for 12 weeks reported decreases in TNF-α, erythrocyte sedimentation rate, and swollen and tender joint counts. The 2023 systematic review of 29 clinical trials lists rheumatoid arthritis among conditions successfully treated with gum arabic.

Krill oil provides omega-3 fatty acids (EPA and DHA) in phospholipid form with higher bioavailability than standard fish oil, plus astaxanthin, an antioxidant. Animal studies show it reduces arthritis scores in collagen-induced arthritis models, and a clinical study (Deutsch) found it reduced CRP and subjective symptoms in RA and OA patients.

Patients with rheumatoid arthritis (RA) consistently show significantly lower serum free histidine levels, with the magnitude of depletion correlating with disease activity. A placebo-controlled RCT of L-histidine supplementation in RA was conducted in the 1970s. While histidine's anti-inflammatory and antioxidant properties provide plausible mechanisms, direct supplementation RCTs have shown limited clinical benefit.

L. casei 01 has been tested in a randomized double-blind clinical trial in female RA patients, showing reductions in DAS28 score, tender/swollen joint counts, hs-CRP, and pro-inflammatory cytokines including TNF-α and IL-12. The strain (10⁸ CFU/day for 8 weeks) also increased anti-inflammatory IL-10. Animal model data with collagen-induced arthritis further supports a mechanistic role for L. casei in reducing synovial inflammation.

Luteolin reduces joint inflammation, cartilage degradation, and inflammatory cytokine production in rheumatoid arthritis preclinical models via NF-κB, MAPK, and synoviocyte apoptosis pathways. It is highlighted in multiple systematic reviews as a promising anti-RA agent.

Altered manganese metabolism is documented in rheumatoid arthritis, with elevated granulocyte manganese correlating with disease activity markers. MnSOD activity is reduced in RA joint tissue. No completed RCT has demonstrated therapeutic benefit of manganese supplementation in RA.

Mangosteen xanthones inhibit the key inflammatory pathways of rheumatoid arthritis—NF-κB, COX-2, TNF-α, and IL-1β—in both in vitro and animal models. A review specifically identifies rheumatoid-relevant inflammation as a target. No human RCTs have focused on rheumatoid arthritis, but the anti-inflammatory human trial evidence is contextually relevant.

MeCbl is used as an adjunct in rheumatoid arthritis (RA), where hyperhomocysteinemia—partly driven by B12 deficiency—contributes to both disease activity and increased cardiovascular risk. MeCbl lowers homocysteine in RA patients. It has also been cited in PMC literature as a condition where MeCbl has clinical use beyond its nutritional role.

Morinda officinalis iridoid glycosides (MOIG) and M. citrifolia extracts have demonstrated anti-arthritic activity in well-characterised animal models. MOIG suppresses synovial fibroblast proliferation and key inflammatory cytokines (IL-1β, IL-6, IL-17a) through MAPK and NF-κB pathway inhibition. Traditional TCM use for rheumatoid arthritis is extensively documented.

MSM is an organosulfur compound with antioxidant and anti-inflammatory properties. A placebo-controlled study found MSM (3 g twice daily) significantly reduced pain and improved function in knee arthritis. ConsumerLab and the Arthritis Foundation list MSM among studied adjunct supplements for RA and related joint conditions.

Rheumatoid arthritis (RA) was one of the specific indications studied in the Siemandi 1997 multicenter RCT, which enrolled patients with RA alongside osteoarthritis and psoriatic arthritis. Animal work by Diehl and May (1994) also specifically demonstrated protective effects against adjuvant-induced polyarthritis. CMO's proposed immune-modulating mechanism is particularly relevant to RA's autoimmune pathology. Evidence remains preliminary and trial quality limited.

Guggulsterone in myrrh has a documented anti-inflammatory role specifically in rheumatoid arthritis. Myrrh ethanolic extract was evaluated in an autoimmune disease animal model showing reduced inflammatory activity. Myrrh is traditionally paired with frankincense in TCM for joint inflammatory conditions.

NAG has demonstrated attenuation of disease severity in collagen-induced arthritis (CIA) animal models, with reductions in synovial inflammatory cell infiltration and immune cell suppression. A mouse RA model showed lower arthritis scores and improved histopathology with dietary NAG at 0.5% for 56 days.

A 2022 randomized double-blind placebo-controlled trial (n=90 RA patients) showed that nettle supplementation significantly decreased the Disease Activity Score DAS28 and pain severity compared to placebo. Earlier clinical data include a German pilot RCT showing nettle plus low-dose diclofenac was as effective as standard diclofenac dose, and preclinical data confirm anti-inflammatory mechanisms via NF-κB inhibition and cytokine suppression.

Extra-virgin olive oil polyphenol-enriched extracts have been shown in a 2025 cell study using PBMCs from RA patients to reduce intracellular ROS and suppress TNF-α and IL-1β, providing direct human cellular evidence. Oleocanthal's COX-1/COX-2 inhibitory activity and oleuropein's NF-κB suppression are mechanistically relevant. Human interventional RCTs in RA patients remain limited.

EVOO polyphenolic extracts suppress key RA-relevant inflammatory pathways in vitro, including MMP-1, MMP-3, COX-2, IL-6, and TNF-α in IL-1β-activated synovial fibroblasts. Epidemiological data from Mediterranean populations link high olive oil consumption with lower RA prevalence. Anti-inflammatory polyphenols in EVOO are considered promising dietary adjuncts to RA management.

Omega-3 fatty acids (EPA and DHA) from marine sources are among the best-evidenced natural supplements for RA, supported by at least 12 RCTs and multiple meta-analyses demonstrating reduced morning stiffness, tender joints, and NSAID requirements. A 2017 systematic review of 22 marine oil trials found moderate-quality evidence of benefit.

GLA, an anti-inflammatory omega-6 PUFA, has been investigated in multiple RCTs for rheumatoid arthritis (RA). A double-blind trial of 56 RA patients using 2.8 g/day purified GLA showed benefit, and a 60-patient RCT found that fish oil combined with evening primrose oil significantly reduced DAS28, tender joint count, and VAS pain scores. Evidence is mixed; a Cochrane review found insufficient data for a reliable assessment of GLA's effectiveness in RA.

PABA has been specifically investigated in small human studies for rheumatoid arthritis, where it was combined with cortisone or aspirin. Studies from the early 1950s reported significant symptomatic benefit in active RA patients. In vitro data show potassium para-aminobenzoate inhibits glycosaminoglycan secretion in rheumatoid synovial cells. All human studies are old and uncontrolled.

The butanol fraction of P. foetida leaf extract showed possible disease-modifying antirheumatic properties in rat models, including inhibition of serum orosomucoid levels and membrane-stabilizing activity. Mechanistically, it suppresses NF-κB, TNF-α, and IL-1β—pathways central to RA pathogenesis.

Feverfew has documented traditional use for rheumatoid arthritis and one published placebo-controlled RCT. The clinical trial (Pattrick et al., 1989) found minimal benefit, with only grip strength significantly improved. In vitro data show parthenolide inhibits ICAM-1 expression on synovial fibroblasts and suppresses NF-κB-driven inflammatory cytokines relevant to RA pathology.

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide with anti-inflammatory and analgesic properties via PPAR-α activation and mast cell stabilization. ConsumerLab lists PEA specifically among studied supplements for RA joint health, and multiple clinical trials support its use for chronic inflammatory pain.

TGP from Paeonia lactiflora is a clinically registered drug in China for rheumatoid arthritis. Multiple meta-analyses of RCTs demonstrate that TGP combined with conventional DMARDs significantly reduces disease activity markers compared to DMARDs alone.

Bromelain has been studied in rheumatoid arthritis with RCTs demonstrating anti-inflammatory and analgesic effects, reduced morning stiffness, and decreased NSAID reliance. Several RCTs have specifically evaluated bromelain in RA populations.

At least two RCTs and one pilot study show pomegranate extract reduces RA disease activity scores, inflammatory biomarkers, and oxidative stress. A 2025 systematic review (PRISMA, ScienceDirect) specifically on rheumatic diseases confirms the evidence from five clinical studies. Pomegranate inhibits NF-κB and synovial cell inflammation in vitro.

A 2025 PMC study tested Zanthoxylum alkaloids in a Freund's adjuvant rat model of rheumatoid arthritis, finding significant joint inflammation reduction and suppression of IL-1β, IL-6, and IL-17A via the SRC/STAT3/MAPK3 pathway. Traditional use for rheumatism is extensively documented. Human clinical evidence is absent.

Puerarin, a C-glucoside isoflavone from kudzu root (Pueraria montana), inhibits NF-κB, reduces inflammatory cytokines, and suppresses osteoclastogenesis in RA. It was included as a distinct RCT arm in a 2025 network meta-analysis of 18 RA clinical trials (1,674 patients), with evidence for reduced disease activity markers.

Quercetin is a flavonoid that suppresses RA-relevant inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8), inhibits NF-κB and fibroblast-like synoviocyte invasion, and reduces osteoclastogenesis. A 2025 network meta-analysis of 18 RA RCTs ranked quercetin as the most effective plant substance for reducing VAS pain scores (SUCRA 67.3%).

Reishi polysaccharides reduce joint inflammation in preclinical rheumatoid arthritis models by suppressing pro-inflammatory cytokines, modulating immune cell polarisation, and inhibiting osteoclastogenesis. Life Extension cites laboratory studies showing reishi extracts demonstrating promise in rheumatoid arthritis and Sjögren's syndrome. No human RCTs in RA have been published.

Resveratrol is a polyphenolic stilbenoid that inhibits NF-κB, COX-2, and inflammatory cytokines relevant to RA. A 2025 network meta-analysis of 18 RA RCTs ranked resveratrol as the most effective plant substance for reducing DAS28 disease activity score (SUCRA 74.3%), a primary clinical outcome in RA.

An RCT (n=89, 6 months) found rosehip powder (5 g daily) improved disease activity, quality of life, and physical function versus placebo in rheumatoid arthritis patients. A 2022 review confirmed rosehip has clinical benefits in rheumatoid arthritis. Rosehip also functions as an immunomodulator, reducing autoimmune-driven joint inflammation.

Rose hips (Rosa canina) contain the anti-inflammatory galactolipid GOPO (galactolipid from rose hip), polyphenols, and vitamin C. Clinical studies and patent literature support rose hips concentrate for alleviating joint pain and stiffness in inflammatory joint diseases including RA. ConsumerLab lists rose hips among studied RA supplements.

Rosmarinic acid induced apoptosis of activated T cells isolated from rheumatoid arthritis patients via the mitochondrial pathway — providing direct human-cell-level evidence of immune modulation in RA. Preclinical animal models confirm RA reduces joint inflammation, cartilage damage, and synovial cytokine production. RA's T-cell apoptosis mechanism is analogous to, but potentially safer than, immunosuppressive drugs used for RA.

R. cordifolia ethanol extract has been evaluated in an adjuvant-induced arthritis (AIA) rat model, with network pharmacology and experimental validation demonstrating reduction of pro-inflammatory mediators TNF-α, IL-1β, and PGE2. The key mechanism involves COX-2 inhibition by alizarin and mollugin, and phospholipase pathway modulation. Traditional use for rheumatism is well-documented across Asian medicine systems.

Rutoside (rutin's semi-pharmaceutical form) inhibited the release of TNF-α, IL-1, IL-6, and nitric oxide from human activated macrophages in vitro and reduced clinical signs of arthritis in an adjuvant-induced rat model. These human macrophage data provide mechanistic clinical relevance.

Salicin (willow bark extract) has been tested in at least one RCT specifically in rheumatoid arthritis (RA) patients. The trial found a 15% pain reduction in the willow bark group versus 4% in placebo, but the difference was not statistically significant, likely due to the small sample size (n=13 per arm). Evidence is present but not confirmatory.

Smilax glabra has documented immunomodulatory activity in adjuvant-induced arthritis rat models, and Smilax ornata was confirmed to have anti-inflammatory and analgesic properties relevant to RA in a 2019 PubMed study. A case report of psoriatic arthritis treatment incorporating sarsaparilla was published in J Chiropr Med (2020). Human trial evidence is limited to a single case report.

The 2016 BMC study (PMC4994400) explicitly lists rheumatoid arthritis alongside osteoporosis as a target for EEST, given its osteoclast-inhibiting and anti-inflammatory properties. Preclinical data are the sole evidence; no human RA trials have been published.

Serratiopeptidase has been investigated for rheumatoid arthritis (RA) as an anti-inflammatory enzyme adjunct, with clinical literature listing it as an indication and experimental work targeting macrophages in RA using SRP-containing formulations. Several clinical reviews and the Bhagat 2013 systematic review list RA among conditions for which SRP has clinical trial data, though trials are small and methodologically weak.

Rheumatoid arthritis is one of the most studied indications for SD, with multiple peer-reviewed preclinical studies using collagen-induced and adjuvant-induced arthritis animal models demonstrating reduced joint inflammation, cytokine suppression, and cartilage protection via NF-κB and MAPK inhibition. A 2025 PMC study also investigated TNF-α and RAGE signaling pathways. Over 130 TCM formulations contain SD for RA. All evidence remains preclinical.

Astilbin from Smilax glabra has been studied specifically in CFA-induced arthritis rat models and collagen-induced arthritis, showing suppression of Th17-mediated and NF-κB-driven joint inflammation. One case report in humans found benefit from a Smilax-containing Ayurvedic formula. Pre-clinical evidence is consistent but human RCTs have not been conducted.

Reduced SPM levels have been measured in synovial fluid and peripheral blood of RA patients. SPMs counter key RA pathomechanisms including synoviocyte proliferation, osteoclast activation, and neutrophil NETosis. In preclinical RA models, SPMs provide sustained pain relief and joint protection without immunosuppression.

Sulforaphane suppresses Th17-driven joint inflammation via Nrf2 and NF-κB modulation, and has been studied in inflammatory joint disease contexts. The psoriasis/SLE preclinical data showing Th17 suppression is mechanistically directly relevant to RA. In vitro and animal data support anti-arthritic activity.

A 2017 human RCT demonstrated A. annua extract reduced symptoms in active rheumatoid arthritis patients. Multiple preclinical studies and a 2025 review in the British Journal of Pharmacology confirm artemisinins modulate key RA pathways including Th17/Treg balance, TNF-α, and synovial fibroblast activity.

Animal studies have shown that Dipsacus asperoides extracts exert antirheumatic effects in collagen-induced arthritis mouse models and inhibit osteoclast differentiation relevant to RA-mediated bone resorption. Traditional classification in Korean and Chinese medicine systems lists RA among its primary indications. No human clinical trials have been conducted.

In a collagen-induced arthritis mouse model, THIAA dose-dependently reduced arthritis index and joint degradation, with efficacy at 250 mg/kg comparable to celecoxib at 20 mg/kg. A 12-week open-label human case series evaluated 150 mg nTHIAA plus undenatured type II collagen in arthritis patients including those with rheumatoid arthritis. THIAA inhibits kinases in the B-cell receptor pathway relevant to autoimmune-mediated joint destruction.

T. cordifolia extract suppresses key RA-relevant immune mediators including IL-1β, TNF-α, IL-6, IL-17, and RANTES in rat adjuvant-induced arthritis, and modulates JAK/STAT and RANKL/MMP-9 pathways to reduce bone and cartilage destruction. It is an established traditional Ayurvedic remedy for RA.

Turmeric (Curcuma longa) contains curcumin and other curcuminoids with potent anti-inflammatory actions relevant to RA, including inhibition of COX-2, NF-κB, and pro-inflammatory cytokines. Multiple RCTs and meta-analyses support its use for reducing RA pain, joint stiffness, and inflammatory markers. Used in Ayurveda for joint disease for centuries.

Observational studies show whole blood pantothenic acid levels are lower in RA patients than healthy controls, with the lowest levels correlating with the most severe symptoms. Small studies of calcium pantothenate supplementation report improvements in morning stiffness and pain, though evidence is preliminary and larger confirmatory trials are lacking.

Folate is co-administered with methotrexate in RA to reduce MTX-induced side effects including mucositis and hepatotoxicity, without compromising anti-arthritic efficacy, as supported by Cochrane reviews and ACR/EULAR RA treatment guidelines. EBSCO Research Starters lists folate as a proposed natural treatment for RA.

Vitamin C is a potent water-soluble antioxidant that reduces oxidative stress in RA joints, modulates immune function, and supports collagen synthesis in damaged cartilage. Rose hips (a studied RA supplement) are among the richest vitamin C sources. Vitamin C deficiency has been linked to increased RA risk and disease severity in epidemiological studies.

Vitamin D modulates immunity by suppressing Th17 cells, reducing IL-17 and pro-inflammatory cytokines central to RA. Multiple meta-analyses document low vitamin D levels in RA patients, and systematic reviews of RCTs show vitamin D supplementation improves disease activity scores, pain, and inflammatory markers in RA.

Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D, with superior efficacy over D2 for raising serum 25(OH)D. It suppresses Th17-driven RA inflammation and promotes regulatory T cells. Multiple RCTs of vitamin D3 supplementation in RA patients show improvements in DAS28, pain, and inflammatory markers.

Vitamin E (tocopherols) reduces oxidative stress in RA joints and has modest anti-inflammatory activity. It is listed by EBSCO Research Starters among proposed natural treatments for RA, and some clinical trials show reductions in pain and inflammatory markers. Vitamin E may serve as an adjunct antioxidant in RA management.

Two randomized double-blind controlled trials (Biegert et al., J Rheumatol 2004) have evaluated white willow bark in both osteoarthritis and rheumatoid arthritis patients. The OA arm showed modest but statistically significant pain reduction over placebo; the small RA arm (13 per group) showed no significant effect versus placebo. A 2023 PMC meta-analysis of five studies with 329 arthritis patients found significant differences in pain relief between willow bark and placebo. Evidence for RA specifically is limited by underpowered trials.

One RCT (Biegert et al., J Rheumatol 2004; n=26 RA patients) compared willow bark extract (240 mg salicin/day) vs. placebo for 6 weeks; no significant effect on pain VAS was observed, and the trial was underpowered. The 2009 systematic review confirmed no significant effect in this study. Preliminary evidence and ESCOP listing of mild rheumatic conditions are insufficient to conclude efficacy specifically in RA; however, trials have been conducted, placing it in the scientific category.

A 2025 systematic review covering 23 studies (11 human) found that yerba mate extracts reduce inflammatory markers such as CRP and IL-6 and improve glutathione-related oxidative balance relevant to RA pathophysiology. No clinical trials have been conducted specifically in RA patients; evidence remains mechanistic and preliminary.

The landmark Bingham et al. (1975) double-blind trial included rheumatoid arthritis patients alongside osteoarthritis patients, finding saponin tablets reduced pain and swelling. A separate 2019 study examined Yucca aloifolia phytochemicals in RA patients and noted reductions in inflammation and oxidative stress markers. The mechanistic basis is inhibition of NFκB and COX pathways by yuccaols and saponins.

Rheumatoid arthritis-relevant preclinical evidence for Zanthoxylum includes suppression of NF-κB, ERK1/2, and pro-inflammatory cytokines in a CFA-induced chronic inflammatory joint pain model. Z. bungeanum polyphenols reduce inflammation via TLR4/MyD88/NF-κB and other pathways implicated in RA pathogenesis.

Zinc is an essential trace mineral involved in immune regulation and antioxidant defense. It is listed among proposed natural treatments for RA by the EBSCO Research Starters and Arthritis Foundation. Some clinical studies show reduced RA disease activity markers with zinc supplementation, consistent with its role in modulating immune cell function.

Adrenal cortex extract is listed among the proposed uses for rheumatoid arthritis in alternative medicine, reflecting the anti-inflammatory role of cortisol and the pre-synthetic-corticosteroid era use of glandular preparations. Contemporary integrative practitioners recommend it for RA. No clinical trial evidence supports OTC adrenal cortex supplements for rheumatoid arthritis.

Alfalfa is traditionally used and listed in pharmacological monographs for rheumatoid arthritis specifically, distinct from general arthritis. RxList and Drugs.com list rheumatoid arthritis as a traditional indication. Caution is warranted given alfalfa's immune-stimulating L-canavanine content, which can worsen autoimmune conditions.

Traditional herbalism consistently lists allspice for rheumatism and joint inflammation. Its anti-inflammatory phytochemicals (eugenol, β-caryophyllene) are mechanistically relevant to autoimmune joint disease. No human evidence distinguishing rheumatoid from osteoarthritis exists for allspice specifically.

Beta-sitosterol has been investigated in animal models of rheumatoid arthritis. In collagen-induced arthritis mice, BSS reduced ankle swelling, bone/cartilage damage, synovial angiogenesis, and VEGFR2 expression, and decreased collagen-specific antibodies via macrophage polarization toward an anti-inflammatory phenotype. Network pharmacology analyses suggest beta-sitosterol modulates FoxO and PI3K/AKT signaling relevant to RA. No human clinical trials in RA patients have been published.

Black cohosh has traditional documentation for rheumatism including rheumatoid arthritis from both Native American practice and 19th-century eclectic medicine. The NIH StatPearls and MHRA list RA as a traditional indication. Modern scientific evidence is limited to proposed anti-inflammatory mechanisms without dedicated RCTs.

Bladderwrack has been specifically prescribed in traditional herbal practice for rheumatoid arthritis, used both orally and topically. Fucoidan's ability to modulate immune-inflammatory pathways relevant to RA (NF-κB, cytokine cascades) provides mechanistic plausibility. Human RA clinical trials are absent.

Buchu's antirheumatic classification in herbal traditions specifically encompasses inflammatory joint conditions akin to rheumatoid arthritis. In vitro COX and 5-LOX inhibitory activity provides a plausible mechanistic basis. No clinical studies in rheumatoid arthritis patients have been conducted.

Cajuput oil is documented in Southeast Asian traditional medicine — particularly Vietnamese folk medicine — as a component in decoctions for rheumatoid arthritis, with a synergistic effect when combined with other plants. Animal studies show M. cajuputi extract downregulates TNF-α and IL-4 in arthritic models (cited for related Eucalyptus globulus combination research). No specific cajuput RCTs exist for RA.

Traditional Korean and Chinese medicine systems have specifically prescribed camphor for rheumatism and inflammatory joint conditions including rheumatoid-type arthritis. The PMC 2025 review documents this use. Camphor's anti-inflammatory and analgesic properties provide biological plausibility, but no clinical trials in rheumatoid arthritis patients have been conducted.

Comfrey has a traditional use for rheumatoid arthritis, documented in historical herbals and modern herbal medicine references, with topical application intended to reduce joint pain and inflammation. RxList lists rheumatoid arthritis among topical traditional uses, and UK practitioners report using comfrey for this condition. Clinical RCTs for rheumatoid arthritis specifically have not been conducted; the evidence in RCTs is for osteoarthritis.

Dioscorea villosa has been used in traditional medicine for rheumatoid arthritis and is documented in Brazilian alternative medicine for this purpose. In vitro evidence shows diosgenin induces apoptosis in RA synoviocytes. Human trials are absent.

GMT has documented traditional use in rheumatic disorders including rheumatoid-type conditions across Greek and Balkan folk medicine, referenced in multiple peer-reviewed ethnobotanical reviews. Its preclinical anti-inflammatory activity (comparable to indomethacin in rodent models) provides mechanistic support. No human RCT in RA patients has been conducted.

Gymnema sylvestre is documented in Ayurvedic tradition for rheumatism and arthritis, including conditions consistent with rheumatoid arthritis. Animal models show relevant anti-inflammatory mechanisms (TNF-α reduction, NF-κB suppression). No human RA-specific clinical trials exist.

The stems of L. japonica (Ren Dong Teng) have a documented TCM indication for rheumatoid arthritis caused by wind-dampness and heat. A preclinical study found that Lonicerae Japonicae Caulis extract inhibits NF-κB and JAK/STAT pathways in rat synovial cells, reducing synovial proliferation. Traditional use includes internal infusions and topical washes for hot, swollen joints.

Horsetail has a documented traditional use for rheumatoid arthritis, appearing in multiple herbal monographs and ethnopharmacological sources. In vitro evidence shows that standardized Equisetum arvense extract dose-dependently inhibits human T-cell proliferation and suppresses IFN-γ and TNF-α—cytokines centrally involved in RA pathogenesis. No clinical trials in RA patients have been conducted.

Rheumatoid arthritis and rheumatism represent core traditional indications of H. indicus in Ayurveda, Siddha, and Unani medicine. Anti-arthritic and anti-inflammatory preclinical evidence supports this traditional use. Topical root paste for rheumatic joints and internal decoction for chronic rheumatism are classically documented.

Rheumatoid arthritis is listed as a traditional indication in Ayurveda and is referenced in RxList, RxList, and the genus Tinospora ethnopharmacology review. Preclinical anti-inflammatory mechanisms (NF-κB inhibition, cytokine suppression) are pharmacologically consistent with RA pathophysiology. No standalone RCT in RA patients has been published.

Rheumatoid arthritis is listed as a specific indication for I. tinctoria in Ayurvedic texts and databases. Anti-arthritic activity has been demonstrated in animal models for the Indigofera genus, and anti-inflammatory mechanisms involving JAK/STAT3 and Th17 suppression are directly relevant to RA pathophysiology.

Syringa plants are used in traditional Chinese medicine to treat rheumatoid arthritis, as documented in the BMC Chemistry genus review. European ethnopharmacology also records the use of lilac infusions and alcoholic extracts topically for rheumatism. Preclinical anti-inflammatory data provide mechanistic plausibility.

Magnesium is an essential mineral involved in over 300 enzymatic reactions. It modulates NF-κB signaling and inflammation; magnesium deficiency is associated with increased inflammatory markers. ConsumerLab lists magnesium among supplements studied for RA and joint health, and use of magnesium supplementation increased significantly in RA patients over time in Australian rheumatology cohort data.

Mustard plasters have a long documented history of use in treating rheumatism and joint inflammation, including rheumatoid conditions. This use is noted in historical pharmacopeia and folk medicine records. AITC's NF-κB inhibitory action offers a mechanistic rationale, but no clinical trials have specifically assessed mustard in diagnosed rheumatoid arthritis populations.

Neem is used traditionally in Ayurveda for rheumatoid conditions; its immunomodulatory properties (CD4+/CD8+ T-cell modulation, cytokine reduction) are mechanistically relevant given RA's autoimmune pathogenesis. The ScienceDirect overview acknowledges antiarthritic properties. No human RCT in RA patients with neem as intervention exists.

Rheumatoid arthritis is listed among traditional indications for P. orientalis in multiple sources. Its anti-inflammatory mechanism—including TNF-α inhibition—is relevant to RA pathophysiology. However, no RA-specific clinical or controlled animal studies with P. orientalis have been published.

Rosmarinic acid from Perilla has documented preclinical anti-inflammatory effects relevant to autoimmune joint diseases including rheumatoid arthritis, via NF-κB and cytokine suppression. Published evidence databases note potential benefit for rheumatoid arthritis based on preclinical anti-inflammatory data. No human clinical trials for RA with perilla have been identified.

In TCM, P. amurense (Huang Bai) is used for 'bi syndrome'—painful, swollen joint conditions encompassing both osteoarthritis and inflammatory arthritis including presentations consistent with rheumatoid arthritis. Its broad anti-inflammatory alkaloids (berberine, phellodendrine) suppress cellular immune responses, and phellodendrine was shown to suppress graft-versus-host reactions in animal models. Clinical trials specifically in rheumatoid arthritis have not been conducted with P. amurense.

Traditional ethnobotanical texts specifically name rheumatoid arthritis as an indication for P. marsupium. COX-2 inhibitory and anti-inflammatory preclinical data offer supporting mechanistic plausibility.

Punarnava is traditionally used in Ayurveda for inflammatory joint conditions including rheumatoid arthritis (amavata). Classical formulations like Punarnavadi Guggulu are specifically prescribed for this condition. Preclinical anti-inflammatory evidence involving cytokine inhibition is mechanistically relevant, but no human trials specifically for rheumatoid arthritis have been conducted.

Queen of the meadow has documented traditional use specifically for rheumatic diseases and arthrosis across European herbal medicine, recognized by the EMA and ESCOP. Pre-clinical evidence of COX inhibition and anti-inflammatory activity provides pharmacological plausibility. No clinical trials in rheumatoid arthritis patients have been conducted.

Rehmannia has a specific traditional role in managing rheumatoid arthritis within TCM, appearing in formulas prescribed for RA and in clinical reports showing improvements in joint pain and swelling. The Restorative Medicine monograph and multiple practitioner references list RA as an established indication.

Safflower has been used in Indian, Persian, and Chinese traditional medicine for rheumatism and joint pain for centuries. The PMC comprehensive review (PMC5984022) specifically cites 'rheumatism' as a clinically associated condition. Preclinical studies support anti-inflammatory mechanisms relevant to rheumatoid arthritis.

Baicalin from S. baicalensis has been studied in collagen-induced arthritis (CIA) rat models and shown to significantly reduce joint symptoms. A 2025 proteomics/metabolomics study (PMC12840285) identified its mechanisms in CIA fibroblast-like synoviocytes. Gaia Herbs cites a 379-patient double-blind RCT using baicalin in an RA/CAD population. Clinical evidence is emerging but limited.

Rheumatoid arthritis is documented as a traditional indication for P. hydropiper across multiple ethnomedicinal systems in Asia and Europe. The plant's decoction has been used as an anti-rheumatic agent. WebMD's monograph lists rheumatoid arthritis as a use. Preclinical anti-inflammatory data lend partial scientific support.

Polygonatum species have been used in TCM and Iranian traditional medicine for rheumatism, and in vitro evidence of TNF-α and interleukin inhibition is consistent with potential relevance to rheumatoid arthritis pathways. No human study has specifically addressed RA. The relationship is traditional, supported by plausible anti-inflammatory phytochemistry.

Tylophora is documented in Ayurvedic medicine and Indian ethnomedicine as an anti-rheumatic agent. The plant's immunomodulatory properties — specifically suppression of cellular immune responses and cytokine inhibition — are mechanistically relevant to rheumatoid arthritis as an autoimmune, inflammatory joint disease. Preclinical anti-arthritic activity has been demonstrated in adjuvant-induced arthritis models. No human RA-specific trial exists.

Adrenal glandular extracts have a historically documented traditional use for rheumatoid arthritis, based on the anti-inflammatory actions of adrenal cortical hormones. Philip Hench's 1949 discovery of cortisone's efficacy in RA, derived from adrenal cortex research, forms the scientific backdrop—but this relates to purified cortisone, not whole glandular supplements. Modern whole adrenal glandular products lack sufficient hormone content to replicate this effect, and no trials exist for the supplement form.

Wild yam has an established traditional use specifically for rheumatoid arthritis, particularly for the acute inflammatory phase. Eclectic herbal texts and contemporary herbalism references cite this use explicitly. Preclinical data show anti-inflammatory mechanisms relevant to RA, but controlled human evidence is absent.

G. procumbens is documented as a traditional herbal medicine for rheumatoid arthritis in Native American ethnomedicine and described as such in a 2024 peer-reviewed phytochemistry review. Methyl salicylate's COX inhibition offers mechanistic plausibility. No clinical trials have evaluated wintergreen specifically in RA patients.

Rheumatoid arthritis is listed as a traditional indication for X. strumarium across multiple ethnomedicinal traditions and in the Bentham Science pharmacological review. The plant appears in Ayurvedic, Chinese, and South Asian traditional systems for autoimmune-pattern joint disease. Anti-inflammatory preclinical data provide mechanistic support; no human RCT data for RA exist.